Sienna Biopharmaceuticals Gets $40M In Series B

Westlake Village-based Sienna Biopharmaceuticals, which is developing medical dermatology and aesthetics treatments, has raised $40M in a Series B funding. The funding was led by ARCH Venture Partners and Venvest Capital, and also included Partner Fund Management, Altitude Life Science Ventures, and Dr. David Pyott, plus new investors Fidelity Management & Research Company, certain investment funds advised by Clough Capital Partners L.P., Omega Fund Management, and others. The company said the funding will go advance its biotech pipeline, which includes pharmaceuticals for treating pruritus and psoriasis; atopic dermatitis, psoriasis and pruritus; and treatment of acne vulgaris and the permanent reduction of unwanted light-pigmented hair. More information »